Sponsor content
18 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Zynlonta (loncastuximab tesirine) has been provisionally approved as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
-
ZYNLONTA loncastuximab tesirine 10 mg powder for concentrate for solution for infusion vial (481165)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZYNLONTA loncastuximab tesirine 10 mg powder for concentrate for solution for infusion vial. -
Prescription medicine decision summaryZynlonta is provisionally approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Zynlonta contains the active ingredient loncastuximab tesirine.
-
Prescription medicine registrationActive ingredients: loncastuximab tesirine.
-
Prescription medicine registrationActive ingredients: pegcetacoplan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Swedish Orphan Biovitrum Pty Ltd - Mechanically-operated infusion pump set.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Swedish Orphan Biovitrum Pty Ltd - Mechanically-operated infusion pump.
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Prescription medicine registrationActive ingredients: pegcetacoplan.